This company is no longer active
CDG Stock Overview
A biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Acorda Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.79 |
| 52 Week High | US$15.90 |
| 52 Week Low | US$0.79 |
| Beta | 1.68 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -93.66% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -91.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| CDG | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | 1.9% |
| 1Y | -93.7% | -4.3% | 15.1% |
Return vs Industry: CDG underperformed the German Biotechs industry which returned -13.3% over the past year.
Return vs Market: CDG underperformed the German Market which returned 5.3% over the past year.
Price Volatility
| CDG volatility | |
|---|---|
| CDG Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CDG's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CDG's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 102 | Ron Cohen | www.acorda.com |
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson’s disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.
Acorda Therapeutics, Inc. Fundamentals Summary
| CDG fundamental statistics | |
|---|---|
| Market cap | €189.55k |
| Earnings (TTM) | -€243.64m |
| Revenue (TTM) | €106.98m |
0.0x
P/S Ratio0.0x
P/E RatioIs CDG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDG income statement (TTM) | |
|---|---|
| Revenue | US$115.66m |
| Cost of Revenue | US$20.48m |
| Gross Profit | US$95.19m |
| Other Expenses | US$358.61m |
| Earnings | -US$263.42m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -212.08 |
| Gross Margin | 82.30% |
| Net Profit Margin | -227.75% |
| Debt/Equity Ratio | -103.1% |
How did CDG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/07/09 03:09 |
| End of Day Share Price | 2024/04/11 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Acorda Therapeutics, Inc. is covered by 28 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert LeBoyer | Aegis Capital Corporation |
| Christopher Raymond | Baird |
| John Newman | Canaccord Genuity |